CHRS (Coherus Oncology, Inc.) Stock Financials & Earnings | Market Cap Arena

CHRS (Coherus Oncology, Inc.) Stock Financials & Earnings | Market Cap Arena

CHRSCoherus Oncology, Inc.

Mkt Cap$226M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$84M

Net Income (TTM)$155M

EPS (TTM)-$1.59

Free Cash Flow (TTM)-$90M

Gross Margin47.8%

Op. Margin-212.4%

Net Margin185.4%

FCF Margin-107.9%

P/S Ratio (TTM)2.7x

P/E Ratio (TTM)1.5x

YoY Rev Growth-63.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$45M	$31M	-$51M
Q1 23	$32M	$16M	-$68M
Q2 23	$59M	$34M	-$35M
Q3 23	$75M	$42M	-$32M
Q4 23	$92M	$7M	-$69M
Q1 24	$2M	$869K	-$68M
Q2 24	$65M	$35M	-$21M
Q3 24	$71M	$50M	-$6M
Q4 24	$54M	$20M	-$42M
Q1 25	$8M	$5M	-$45M
Q2 25	$10M	$7M	-$45M
Q3 25	$12M	$8M	-$44M

Valuation

Quarter	P/S	P/E
Q4 22	1.1x	—
Q1 23	1.2x	—
Q2 23	1.2x	—
Q3 23	1.1x	—
Q4 23	0.9x	—
Q1 24	1.0x	—
Q2 24	1.0x	—
Q3 24	1.0x	—
Q4 24	1.2x	7.9x
Q1 25	1.1x	—
Q2 25	1.6x	1.3x
Q3 25	2.7x	1.5x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$100M	-$100M
Q1 23	-$69M	-$69M
Q2 23	-$39M	-$39M
Q3 23	-$54M	-$54M
Q4 23	-$13M	-$13M
Q1 24	-$47M	-$47M
Q2 24	$60M	$60M
Q3 24	-$62M	-$62M
Q4 24	$29M	$29M
Q1 25	-$26M	-$26M
Q2 25	-$47M	-$47M
Q3 25	-$46M	-$46M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$87K
Q1 23	$152K
Q2 23	$100K
Q3 23	$0
Q4 23	$34K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-38.2%	-14.2%
Q1 23	-46.0%	-29.0%
Q2 23	-2.4%	-10.5%
Q3 23	+64.2%	-15.3%
Q4 23	+101.8%	+65.7%
Q1 24	-92.9%	-30.0%
Q2 24	+10.7%	-8.3%
Q3 24	-5.1%	-27.6%
Q4 24	-40.8%	-39.9%
Q1 25	+229.2%	-24.3%
Q2 25	-84.2%	-34.8%
Q3 25	-83.7%	-27.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$12M	25.9%
Q1 23	$12M	37.9%
Q2 23	$10M	17.2%
Q3 23	$10M	13.3%
Q4 23	$11M	11.8%
Q1 24	$7M	317.1%
Q2 24	$0	0.0%
Q3 24	$6M	9.1%
Q4 24	$6M	11.8%
Q1 25	$5M	70.7%
Q2 25	$5M	52.9%
Q3 25	$3M	29.3%

OpEx Breakdown

Quarter	R&D	SG&A
Q4 22	$29M	$54M
Q1 23	$34M	$49M
Q2 23	$23M	$45M
Q3 23	$26M	$48M
Q4 23	$26M	$49M
Q1 24	$28M	$40M
Q2 24	$21M	$35M
Q3 24	$22M	$35M
Q4 24	$21M	$41M
Q1 25	$24M	$26M
Q2 25	$26M	$26M
Q3 25	$27M	$23M

Revenue Segments

Quarter	Other	Product Revenue	Product	Product and Service, Other
Q1 23	$83K	$32M	—	—
Q2 23	$259K	$58M	—	—
Q3 23	$204K	$74M	—	—
Q2 24	$7M	$58M	—	—
Q3 24	—	—	$71M	$220K

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$64M	$128M	$192M
Q1 23	$17M	$112M	$129M
Q2 23	$73M	$72M	$145M
Q3 23	$81M	$51M	$132M
Q4 23	$103M	$15M	$118M
Q1 24	$260M	$0	$260M
Q2 24	$159M	$0	$159M
Q3 24	$98M	$0	$98M
Q4 24	$126M	$0	$126M
Q1 25	$82M	$0	$82M
Q2 25	$217M	$21M	$238M
Q3 25	$103M	$88M	$192M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	78M	+0.3%
Q1 23	79M	+1.7%
Q2 23	87M	+10.1%
Q3 23	98M	+12.0%
Q4 23	111M	+14.1%
Q1 24	126M	+12.6%
Q2 24	115M	-8.5%
Q3 24	115M	+0.3%
Q4 24	115M	+0.2%
Q1 25	116M	+0.4%
Q2 25	116M	+0.2%
Q3 25	116M	+0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	—	—
FY 14	$471K	66
FY 15	$276K	109
FY 16	$1M	152
FY 17	$13K	122
FY 18	$7K	232
FY 19	$1M	291
FY 20	$2M	317
FY 21	$984K	332
FY 22	$588K	359
FY 23	$841K	306
FY 24	$872K	306